MXPA01010177A - Modulacion de la funcion del tejido excitable mediante eritropoyetina administrada en forma periferica. - Google Patents
Modulacion de la funcion del tejido excitable mediante eritropoyetina administrada en forma periferica.Info
- Publication number
- MXPA01010177A MXPA01010177A MXPA01010177A MXPA01010177A MXPA01010177A MX PA01010177 A MXPA01010177 A MX PA01010177A MX PA01010177 A MXPA01010177 A MX PA01010177A MX PA01010177 A MXPA01010177 A MX PA01010177A MX PA01010177 A MXPA01010177 A MX PA01010177A
- Authority
- MX
- Mexico
- Prior art keywords
- erythropoietin
- excitable
- function
- tissues
- excitable tissue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan los metodos y las composiciones para proteger o mejorar la funcion del tejido excitable en mamiferos por administracion sistemica de un modulador de la actividad del receptor para eritropoyetina, como puede ser la eritropoyetina la cual se indica por un receptor activado por EPO para modular la funcion del tejido excitable. Los tejidos excitables incluyen los tejidos neuronales centrales como el cerebro, tejidos neuronales perifericos, retina y el tejido cardiaco. La proteccion de los tejidos excitables ofrece un tratamiento de hipoxia, trastornos convulsivos, enfermedades neurodegenerativas, hipoglucemia y envenenamiento por neurotoxinas. El mejoramiento de la funcion es util en el aprendizaje y la memoria. La invencion tambien se dirige a las composiciones y los metodos para facilitar el transporte de las moleculas a traves de las barreras hermeticas de las celulas endoteliales, como puede ser la barrera hematoencefalica, mediante la asociacion de las moleculas con un modulador de la actividad del receptor para eritropoyetina, como puede ser una eritropoyetina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29093899A | 1999-04-13 | 1999-04-13 | |
US54722000A | 2000-04-11 | 2000-04-11 | |
PCT/US2000/010019 WO2000061164A1 (en) | 1999-04-13 | 2000-04-13 | Modulation of excitable tissue function by peripherally administered erythropoietin |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA01010177A true MXPA01010177A (es) | 2004-09-10 |
Family
ID=26966493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA01010177A MXPA01010177A (es) | 1999-04-13 | 2000-04-13 | Modulacion de la funcion del tejido excitable mediante eritropoyetina administrada en forma periferica. |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1171147A4 (es) |
JP (1) | JP2003520194A (es) |
KR (2) | KR100883232B1 (es) |
CN (1) | CN1607957B (es) |
AU (1) | AU784550B2 (es) |
BG (1) | BG65353B1 (es) |
BR (1) | BR0009737A (es) |
CA (1) | CA2383940A1 (es) |
CR (1) | CR6501A (es) |
CZ (1) | CZ20013695A3 (es) |
EA (1) | EA004766B1 (es) |
HU (1) | HUP0201598A3 (es) |
IL (2) | IL145895A0 (es) |
IS (1) | IS6104A (es) |
MX (1) | MXPA01010177A (es) |
NO (1) | NO20014991L (es) |
NZ (4) | NZ514690A (es) |
PL (1) | PL352223A1 (es) |
SK (1) | SK14412001A3 (es) |
TR (2) | TR200103785T2 (es) |
WO (1) | WO2000061164A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
ATE444077T1 (de) * | 2000-06-30 | 2009-10-15 | Tokyo Metropolitan Inst Of Ger | Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungen |
DE10043457A1 (de) * | 2000-09-04 | 2002-03-28 | Hannelore Ehrenreich | Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen |
US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
MXPA03006952A (es) * | 2001-02-02 | 2004-10-15 | Johnson & Johnson | Tratamiento de disfuncion neurologica que comprende sulfamatos de fructopiranosa y eritropoyetina. |
US20030118630A1 (en) * | 2001-12-07 | 2003-06-26 | Anthony Cerami | Immune modulation device for use in animals |
CA2465007C (en) | 2001-10-29 | 2012-01-17 | Crucell Holland B.V. | Methods and means for producing proteins with predetermined post-translational modifications |
ATE384785T1 (de) | 2001-12-07 | 2008-02-15 | Crucell Holland Bv | Herstellung von viren, virusisolaten, und impfstoffen |
US7335490B2 (en) | 2002-01-09 | 2008-02-26 | Crucell Holland B.V. | Use of erythropoietin for the preventive or curative treatment of cardiac failure |
AU2002307635A1 (en) * | 2002-04-19 | 2003-11-03 | Crucell Holland B.V. | Methods and means for producing proteins with predetermined post-translational modifications |
GB0211578D0 (en) | 2002-05-21 | 2002-06-26 | Univ Belfast | Medicaments |
EP1552298A4 (en) * | 2002-07-01 | 2006-11-08 | Kenneth S Warren Inst Inc | RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF |
DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
US7396913B2 (en) | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
EP1633383A4 (en) * | 2003-03-27 | 2008-05-21 | Janssen Pharmaceutica Nv | USE OF ERYTHROPOIETIN FOR RE-ESTABLISHMENT FOLLOWING A CEREBRAL ISCHEMIC ACCIDENT |
US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
DK1623023T3 (da) | 2003-05-09 | 2009-03-02 | Crucell Holland Bv | Kulturer af E1-immortaliserede celler og fremgangsmåder til dyrkning deraf til forögelse af produktudbytter derfra |
DE102004063927A1 (de) * | 2004-01-23 | 2005-12-15 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
AT500929B1 (de) | 2004-11-09 | 2007-03-15 | Medizinische Uni Wien Muw | Pharmazeutische zubereitung die erythropoietin enthält |
HUE035793T2 (en) | 2005-08-05 | 2018-05-28 | Araim Pharmaceuticals Inc | Cell protection peptides and their applications |
US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
GB0525540D0 (en) * | 2005-12-15 | 2006-01-25 | Isis Innovation | New treatment |
DE102006004008A1 (de) | 2006-01-27 | 2007-08-02 | Hannelore Prof. Dr. Dr. Ehrenreich | Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose |
CN101062407A (zh) * | 2006-04-29 | 2007-10-31 | 中国科学院上海生命科学研究院 | 促红细胞生成素在预防或治疗视网膜损伤中的用途 |
US8133860B2 (en) * | 2006-07-20 | 2012-03-13 | Rosalind Franklin University Of Medicine And Science | Facilitation of resuscitation from cardiac arrest by erythropoietin |
WO2008086025A2 (en) * | 2007-01-10 | 2008-07-17 | Edison Pharmaceuticals, Inc. | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
WO2009010107A1 (en) * | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
KR20180041269A (ko) | 2008-01-22 | 2018-04-23 | 아라임 파마슈티칼즈, 인크. | 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체 |
RU2519695C2 (ru) * | 2010-07-21 | 2014-06-20 | Олег Ильич Эпштейн | Лекарственное средство для лечения синдрома дефицита внимания и способ лечения синдрома дефицита внимания |
CN111066727B (zh) * | 2019-12-20 | 2021-08-27 | 中国人民解放军陆军军医大学 | 在低氧性血睾屏障通透中作用机制的小鼠模型构建方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6197229A (ja) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
US5661125A (en) * | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
DE19857609A1 (de) * | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
-
2000
- 2000-04-13 NZ NZ514690A patent/NZ514690A/en not_active IP Right Cessation
- 2000-04-13 CN CN008087466A patent/CN1607957B/zh not_active Expired - Lifetime
- 2000-04-13 TR TR2001/03785T patent/TR200103785T2/xx unknown
- 2000-04-13 SK SK1441-2001A patent/SK14412001A3/sk not_active Application Discontinuation
- 2000-04-13 PL PL00352223A patent/PL352223A1/xx not_active Application Discontinuation
- 2000-04-13 CA CA002383940A patent/CA2383940A1/en not_active Abandoned
- 2000-04-13 KR KR1020017013093A patent/KR100883232B1/ko not_active IP Right Cessation
- 2000-04-13 HU HU0201598A patent/HUP0201598A3/hu unknown
- 2000-04-13 NZ NZ560696A patent/NZ560696A/xx not_active IP Right Cessation
- 2000-04-13 EP EP00923344A patent/EP1171147A4/en not_active Ceased
- 2000-04-13 NZ NZ545478A patent/NZ545478A/en not_active IP Right Cessation
- 2000-04-13 TR TR2004/02194T patent/TR200402194T2/xx unknown
- 2000-04-13 IL IL14589500A patent/IL145895A0/xx unknown
- 2000-04-13 BR BR0009737-3A patent/BR0009737A/pt not_active Application Discontinuation
- 2000-04-13 CZ CZ20013695A patent/CZ20013695A3/cs unknown
- 2000-04-13 WO PCT/US2000/010019 patent/WO2000061164A1/en active IP Right Grant
- 2000-04-13 AU AU43487/00A patent/AU784550B2/en not_active Expired
- 2000-04-13 JP JP2000610496A patent/JP2003520194A/ja active Pending
- 2000-04-13 EA EA200101073A patent/EA004766B1/ru not_active IP Right Cessation
- 2000-04-13 MX MXPA01010177A patent/MXPA01010177A/es active IP Right Grant
- 2000-04-13 KR KR1020077021154A patent/KR101012932B1/ko not_active IP Right Cessation
- 2000-04-13 NZ NZ533098A patent/NZ533098A/en not_active IP Right Cessation
-
2001
- 2001-10-11 IL IL145895A patent/IL145895A/en not_active IP Right Cessation
- 2001-10-11 IS IS6104A patent/IS6104A/is unknown
- 2001-10-12 NO NO20014991A patent/NO20014991L/no not_active Application Discontinuation
- 2001-10-26 BG BG106058A patent/BG65353B1/bg unknown
- 2001-11-13 CR CR6501A patent/CR6501A/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA01010177A (es) | Modulacion de la funcion del tejido excitable mediante eritropoyetina administrada en forma periferica. | |
ES2131525T3 (es) | Usos terapeuticos de la melanina. | |
PH12016500941A1 (en) | Protection, restoration, and enhancement for erythropoietin-responsive cells, tissues and organs | |
ATE244572T1 (de) | Peptid-lipid konjugate, liposomen und liposomale arzneimittelverabreichung | |
ATE314067T1 (de) | Cannabinol-11-säurederivate als entzündungshemmer und analgetika | |
ES2163034T3 (es) | Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana. | |
EP0984930A4 (en) | 2-INDOLINE DERIVATIVES AS MODULATORS OF THE PROTEIN KINASE ATIVITY | |
DK0909183T3 (da) | DHA-konjugerede farmaceutisk midler | |
BR9714677A (pt) | "enantiÈmeros 3-piridila e seu uso como analgésicos" | |
WO1994006449A3 (en) | Morphogen-induced liver regeneration | |
Veiga et al. | Anti-aging peptides for advanced skincare: focus on nanodelivery systems | |
WO2002100836A3 (en) | Compounds, compositions and methods for modulating beta-amyloid production | |
DE68928169D1 (de) | Zusammensetzung zur Behandlung von degenerativen Krankheiten des Nervensystems | |
US20070154437A1 (en) | Peptide-tagged proteins and methods of making and using thereof | |
EP1020192A3 (de) | Anticellulitiszusammensetzung und ihre Verwendung | |
US20040043463A1 (en) | Peptide-tagged proteins and compositions for regulating features of the skin or hair; methods of making, and methods of using thereof | |
CA2255748A1 (en) | Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders | |
Zhu et al. | The dynamic change and regulation of IGF-1 on axonal regeneration after sciatic nerve transaction | |
DE69724228D1 (de) | Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten | |
WO1999038967A3 (en) | Recombinant proteins derived from hgf and msp | |
KR20220161685A (ko) | 점막미백주사액 및 그 제조방법 | |
TH19132B (th) | วิธีการทำให้บริเวณผิวหนังของสัตว์เลี้ยงลูกด้วยนมที่มีสารสีมากเกิดไปจางลง | |
TH19132A (th) | วิธีการทำให้บริเวณผิวหนังของสัตว์เลี้ยงลูกด้วยนมที่มีสารสีมากเกิดไปจางลง | |
JPS61137817A (ja) | 色素増強疾患治療剤 | |
IT1267955B1 (it) | Derivati solfatati dei lisogangliosidi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights | ||
FG | Grant or registration |